Exelixis (Nasdaq: EXEL) reported that its phase 3 STELLAR-303 trial evaluating zanzalintinib combined with atezolizumab in metastatic colorectal cancer did ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA